|
AMB-FUBINACA
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 10.04 nM at CB1 and 0.786 nM at CB2 and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2, and has been sold online as a designer drug. It was originally developed by Pfizer which described the compound in a patent in 2009, but was later abandoned and never tested on humans. AMB-FUBINACA was the most common synthetic cannabinoid identified in drug seizures by the Drug Enforcement Administration in 2017 and the first half of 2018. Mass casualties On July 12, 2016, the New York City Emergency Medical Services responded to a "mass casualty event" in Brooklyn, New York, where 33 people ranging in age from 25 to 59 years old were adversely affected by the drug. 18 were hospitalized. All of the victims were described by by-standers as “zombielike” and the cause was attributed ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. These novel Psychoactive drug, psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis) or synthetic Cannabinoid, endocannabinoids from which they are distinct in many aspects. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the United States and United Kingdom since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names such as K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid leg ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabis
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that bind to the same receptors to which cannabinoids ( THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis) or synthetic endocannabinoids from which they are distinct in many aspects. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the United States and United Kingdom since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names such as K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid legal restrictions on cannabis, making synthetic cannabinoids designer drugs. Most s ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-FUBINACA
AB-FUBINACA ( AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported. Its use has been linked to hospitalizations and deaths. Legality United States of America It was designated as a Schedule I controlled substance in the United States in January 2014. Finland In Finland AB-FUBINACA is scheduled in government decree on psychoactive substances banned from the consumer market as of 19 October 2017. Germany It is an Anlage II controlled substance in Germany as of November 2014. China Since October 2015 AB-FUBINACA is a controlled subs ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-AMB
5F-AMB (also known as 5F-MMB-PINACA and 5F-AMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in early 2014. Although only very little pharmacological information about 5F-AMB itself exists, its 4-cyanobutyl analogue (instead of 5-fluoropentyl) has been reported to be a potent agonist for the CB1 receptor (''K''I = 0.7 nM). Side effects 5F-AMB intoxication caused one fatality on its own, another through ketoacidosis in combination with AB-CHMINACA, AB-FUBINACA, AM-2201, 5F-APINACA, EAM-2201, JWH-018, JWH-122, MAM-2201, STS-135 and THJ-2201 and another fatality in combination with AB-CHMINACA and Diphenidine. Legality In the United States, 5F-AMB is a Schedule I controlled substance. 5F-AMB is an Anlage II controlled substance in Germany as of May 2015. Sweden's public health agency suggested classify ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-FUBINACA
ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide. The (''S'')-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ... of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-CHMINACA
MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication. Legal status MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015. MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015. Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019. See also * AB-CHMINACA * ADB-CHMINACA * ADB-FUBINACA ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-CHMICA
MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA. Chemistry Several commercial samples of MDMB-CHMICA were found to exclusively contain the (''S'')-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography. An (S)-configuration for the ''tert''-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive "L" form of the appropriate ''tert''-leucinate reactant. Pharmacology MDMB-CHMICA acts as a highly potent full agonist of the CB1 receptor with an efficacy of 94% and an EC50 value of 0.14 nM, which is approximately 8 times lower than the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-ADB
5F-ADB (also known as MDMB-5F-PINACA using systematic EMCDDA nomenclature and 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F-ADB is a potent agonist of the CB1 receptor, though it is unclear whether it is selective for this target. 5F-ADB was first identified in November 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. 5F-ADB is believed to be extremely potent based on the very low levels detected in tissue samples, and appears to be significantly more toxic than earlier synthetic cannabinoid drugs that had previously been sold. In 2018, 5F-ADB was the most ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Diário Oficial Da União
The ''Diário Oficial da União'' (literally ''Official Diary of the Union''), abbreviated DOU, is the government gazette, official gazette of the Federal Government of Brazil, Federal Government of Brazil. It is published since 1 October 1862 and was created via the Imperial Decree 1,177 of its 9 September as the ''Official Journal of the Empire of Brazil''. Its current name was adopted after Brazil became a federal republic, and the "Union" came into being as the legal personality of the new federal government. The official journal is published by the Imprensa Nacional, Brazilian National Press. Though the journal has been published since 1862, it had many predecessors, as follows: # Gazeta do Rio de Janeiro (10/9/1808 – 29.12.1821) # Gazeta do Rio (1/1/1822 – 31/12/1822) # Diário do Governo (2/1/1823 – 28/6/1833) # Diário Fluminense (21/5/1824 – 24/4/1831) # Correio Oficial (1/7/1833 – 30/6/1836) e (2/1/1830 – 30/12/1840) # Without proper journal (31/12/1840 – ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (''K''i = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (''K''i = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status Germany AB-PINACA is an Anlage II controlled substance in Germany as of November 2014. Singapore It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015. United States It is a Schedule I controlled substance in the United States. China It is a controlled substance in China as of October 2015. France It is a contr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADSB-FUB-187
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of ''K''i, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values. Legality Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products. See also * AB-FUBINACA * ADB-FUBINACA * ADB-5'F-BUTINACA * ADB-5'Br-PINACA ADB-5'Br-PINACA (5'-Br-ADB-PINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Abu Dhabi i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-CHMINACA
ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. Side effects There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status In the United States, ADB-CHMINACA is a Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014. Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014. ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. ADB-CHMINACA is illegal in Switzerland as o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
